Publications by authors named "Geraldine Navarro"
Article Synopsis
- Calcium pyrophosphate deposition (CPPD) disease is common but previously lacked validated classification criteria, which have now been developed by the American College of Rheumatology (ACR) and EULAR.
- A multinational group established these criteria by generating lists of candidate items, refining definitions, and validating the framework through patient profiles and statistical analysis.
- The new criteria allow for CPPD classification based on specific symptoms, testing results, and a scoring system, demonstrating high sensitivity and specificity in identifying the disease.
Article Synopsis
- Calcium pyrophosphate deposition (CPPD) disease lacks established classification criteria, prompting the American College of Rheumatology (ACR) and EULAR to create the first validated criteria for symptomatic cases.
- A multinational team developed these criteria by analyzing patient profiles, defining candidate items, and employing decision-making methods to establish a scoring system for classification.
- The new criteria showed high sensitivity (92.2% in one cohort; 99.2% in another) and specificity (87.9% and 92.5%, respectively), making them effective tools for diagnosing CPPD disease and advancing research.
Objective: Within rheumatoid arthritis (RA) patients treated with intravenous tocilizumab (IV-TCZ), it is unclear if power Doppler ultrasonography (PDUS) can predict future clinical response. This study sought to determine if baseline PDUS or its early changes can predict 12-week and 24-week disease activity outcomes, and quantify the need for dose escalation (4 to 8 mg/kg).
Methods: Fifty-four RA patients starting IV-TCZ were evaluated at baseline, 4, 6, 12, 16, and 24 weeks using 34-joint PDUS (US34-PDUS), clinical disease activity index (CDAI), 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR), ACR 20/50/70, health assessment questionnaire-disability index (HAQ-DI), and PDUS 20/50/70, a novel measure.
Introduction: Tocilizumab (TCZ) is a biological agent used for the treatment of moderate to severe rheumatoid arthritis (RA). In the present systematic literature review and meta-analysis, we provide an update on the efficacy and safety of TCZ and our clinical comments for the treatment of RA.
Methods: We searched PubMed for randomized, double-blind, placebo-controlled clinical trials investigating the effects of TCZ on RA.